Therapeutic Asset Ratings
200 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Dasatinib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Ruijin Hospital
P1/2
CC
(43)
Sonrotoclax
Large B-Cell Lymphoma
Ruijin Hospital
P1/2
CC
(43)
BMS-986345
Diffuse Large B Cell Lymphoma
Ruijin Hospital
P1
CC
(42)
Duvelisib
Diffuse Large B-Cell Lymphoma
Ruijin Hospital
P1
CC
(42)
abo2203
B-Cell Non-Hodgkin Lymphoma
Ruijin Hospital
P1
CC
(41)
Anti-Meso Car T Cells
Refractory Malignant Neoplasm
Ruijin Hospital
P1
CC
(41)
Lcar-Hl30 Cells
Anaplastic Large Cell Lymphoma
Ruijin Hospital
P1
CC
(41)
ntf001
ALS (Amyotrophic Lateral Sclerosis)
Ruijin Hospital
P1
CC
(41)
pd-1 knockout engineered t cells
Autosomal Dominant Parkinson Disease 1
Ruijin Hospital
P1
CC
(41)
pd1-til
Autosomal Dominant Parkinson Disease 1
Ruijin Hospital
P1
CC
(41)
Spartalizumab
Parkinson Disease
Ruijin Hospital
P1
CC
(40)
pd-1 knockout engineered t cells
Colorectal Cancer
Ruijin Hospital
P1
C
(39)
pd1-til
Colorectal Cancer
Ruijin Hospital
P1
C
(39)
Clozapine
Gene Therapy
Ruijin Hospital
Early P1
C
(39)
Clozapine
Safety and Efficacy
Ruijin Hospital
Early P1
C
(39)
Personalized Neoantigen Tumor Vaccine
Chemotherapy-intolerant
Ruijin Hospital
Early P1
C
(39)
abo2102
Other Solid Tumors
Ruijin Hospital
Early P1
C
(38)
abo2102
Pancreatic Neoplasm
Ruijin Hospital
Early P1
C
(38)
Personalized Neoantigen Tumor Vaccine
Malignant Pancreatic Neoplasm
Ruijin Hospital
Early P1
C
(38)
Personalized Neoantigen Tumor Vaccine
Pancreatic Adenocarcinoma
Ruijin Hospital
Early P1
C
(38)
Toripalimab
Other Solid Tumors
Ruijin Hospital
Early P1
C
(38)
Hekt Cell
Non-Small Cell Lung Carcinoma
Ruijin Hospital
P1
C
(37)
Clozapine
Parkinson Disease
Ruijin Hospital
Early P1
C
(37)
ABO2109
Solid Tumor
Ruijin Hospital
Early P1
C
(33)
es502
Pancreatic Neoplasm
Ruijin Hospital
Early P1
C
(33)
Showing 151 to 175 of 200 assets
Previous
Page 7 of 8
Next